Acetylsalicylic Acid

證據等級: L5

預測適應症: 9 個

Acetylsalicylic Acid (Aspirin): From Cardiovascular Prevention to Migraine with Brainstem Aura

One-Sentence Summary

Acetylsalicylic acid (Aspirin, DB00945) is one of the world’s most widely used drugs, classically indicated for analgesia, antipyresis, anti-inflammation, and antiplatelet-mediated cardiovascular protection. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, with 0 clinical trials and 19 publications currently supporting this direction. The overall evidence is rated L3, based on retrospective studies and reviews; targeted prospective research is needed before any clinical advancement.

Quick Overview

Item	Content
Original Indication	Pain, fever, anti-inflammation, and cardiovascular prevention (antiplatelet); no India regulatory record in dataset
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.94%
Evidence Level	L3
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from the automated regulatory database query for this candidate. Based on established pharmacological knowledge, Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) at the Ser529 residue, permanently blocking platelet thromboxane A2 (TXA2) biosynthesis for the entire platelet lifespan (~7–10 days). Aspirin also inhibits COX-2 at higher doses, reducing prostaglandin synthesis and mediating its analgesic and anti-inflammatory effects across tissues.

Migraine with brainstem aura (formerly “basilar-type migraine”) is a distinct ICHD-III subtype characterized by neurological symptoms referable to the brainstem — including dysarthria, vertigo, tinnitus, diplopia, and ataxia — before the headache phase. The mechanistic link to Aspirin runs through two complementary pathways: (1) Cortical spreading depression (CSD), the electrophysiological correlate of aura, is associated with platelet activation and TXA2-mediated vasoconstriction particularly in the posterior circulation; Aspirin’s antiplatelet action may interrupt this vascular cascade. (2) Neurogenic inflammation in the trigeminovascular system, driven partly by prostaglandins, amplifies pain signaling; Aspirin’s COX inhibition may dampen this trigeminal sensitization.

However, brainstem aura is a rare and clinically distinct subtype, and virtually all existing clinical evidence pertains to “migraine with aura” as a broader category. A retrospective study (PMID 25729594) demonstrated prophylactic benefit of low-dose Aspirin in migraine with aura broadly, and a 2025 systematic review (PMID 39989443) specifically assessed antithrombotic drugs in migraine prevention. No RCT has been conducted specifically enrolling brainstem aura patients. The TxGNN high prediction score (99.94%) likely reflects topological proximity in the disease knowledge graph between aura-type migraine and brainstem aura, rather than direct clinical data — warranting cautious interpretation.

Clinical Trial Evidence

Currently no related clinical trials registered specifically for Aspirin in migraine with brainstem aura.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10448545	1999	Double-blind RCT	Cephalalgia	278 acute migraine patients (with or without aura) randomized to IV lysine acetylsalicylate 1.8 g vs subcutaneous sumatriptan 6 mg vs placebo; both active agents were superior to placebo, establishing Aspirin’s acute efficacy in migraine
25729594	2014	Retrospective Study	Current Health Sciences Journal	203 migraine-with-aura patients (ICHD-II); 46.8% received low-dose ASA for prophylaxis over ≥4 months — demonstrates real-world feasibility and tolerability of Aspirin in aura-type migraine prevention
39989443	2025	Systematic Review	Headache	First systematic review specifically examining the role of antithrombotic drugs (including Aspirin) as migraine preventive medication; evaluates mechanistic plausibility and the available clinical evidence base
25600718	2015	Evidence Assessment / Guideline	Headache	American Headache Society updated evidence assessment of acute migraine pharmacotherapies; Aspirin and aspirin-combination products receive Level A evidence for mild-to-moderate migraine attacks
35006660	2022	Guideline	FP Essentials	AHA/ASA primary stroke prevention guidelines classify migraine with aura as an independent vascular risk factor; directly relevant context given brainstem aura’s posterior circulation involvement and elevated stroke risk
34384631	2021	Review	Revue Neurologique	Comprehensive review of migraine with aura covering CSD mechanism and ICHD-III diagnostic criteria; provides the pathophysiological framework underpinning Aspirin’s plausible anti-CSD mechanism
30291554	2018	Review	Current Pain and Headache Reports	Systematic comparison of migraine with and without aura: distinct vascular risk profiles, pathophysiology, and management implications — supports a differentiated therapeutic approach for aura-type migraine
2701286	1989	Review	Biomedicine & Pharmacotherapy	Foundational 10-year review of the platelet hypothesis of migraine; presents evidence that primary platelet abnormalities (excess TXA2, abnormal serotonin uptake) contribute to migraine attacks — core mechanistic rationale for Aspirin’s antiplatelet approach
26908949	2016	RCT	European Heart Journal	PRIMA trial: multicentre RCT of percutaneous PFO closure vs medical management (including antiplatelet agents) in patients with refractory migraine with aura — demonstrates vascular-cardiac pathophysiology in aura-type migraine and the relevance of antiplatelet therapy
16103551	2005	Observational	Heart	Clopidogrel (an antiplatelet agent of a different drug class) reduced migraine-with-aura frequency after transcatheter closure of PFO and ASD — supports a class-level antiplatelet mechanism effect applicable to Aspirin in aura-type migraine

Safety Considerations

Drug Interactions (657 interactions identified):

The most clinically significant interactions are listed below:

Interacting Drug	Level	Clinical Relevance
Acalabrutinib	Major	Enhanced hemorrhagic risk; concurrent use should be avoided
Acetazolamide	Major	Risk of salicylate toxicity due to increased renal reabsorption
Ketorolac	Major	Additive GI toxicity and bleeding risk; combination contraindicated
Fondaparinux	Major	Additive bleeding risk; monitor closely if combined
Trastuzumab emtansine	Major	Significantly enhanced hemorrhagic adverse events
Ibuprofen	Major	Ibuprofen competitively antagonizes Aspirin’s antiplatelet effect at COX-1; avoid concurrent use in cardiovascular protection settings
Abciximab	Moderate	Additive antiplatelet effects; bleeding risk increased
Ethanol	Moderate	Increased gastrointestinal bleeding risk
Fluvoxamine	Moderate	Enhanced bleeding risk via serotonin-mediated platelet inhibition
Hydrocortisone	Moderate	Reduced Aspirin efficacy; additive GI mucosal injury

A total of 657 drug-drug interactions have been identified in the DDInter database. Key warnings and contraindications data were not retrievable from this dataset — please refer to the current approved package insert for complete safety information before clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for Aspirin in migraine with brainstem aura is biologically plausible — antiplatelet suppression of TXA2-mediated posterior circulation vasospasm and anti-neuroinflammatory effects on the trigeminovascular system both provide a credible rationale. However, no clinical trials exist for this specific ICHD-III subtype, and available evidence (L3) derives entirely from broader aura-type migraine populations or indirect mechanistic studies. The clinical distinction between general migraine with aura and the brainstem aura subtype is important and not bridged by current evidence.

To proceed, the following is needed:

Design a prospective pilot cohort or crossover study specifically enrolling patients with confirmed migraine with brainstem aura (ICHD-III criterion 1.2.2), with Aspirin as prophylactic intervention
Retrieve complete MOA data from the DrugBank API (DB00945) and regulatory package inserts to address current data gaps before mechanism-based claims are formalized
Obtain full safety profile (key warnings, contraindications) from the package insert; this is a Blocking data gap that must be resolved before any S1 safety pre-assessment
Evaluate bleeding risk in the target population — particularly in women of reproductive age, where Aspirin use during pregnancy requires careful monitoring
Assess whether evidence from the 2025 antithrombotic systematic review (PMID 39989443) and the retrospective aura study (PMID 25729594) can support a formal research protocol for the brainstem aura subtype, potentially through collaboration with neurology headache centers
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.